AACR 2024 | Developing LSC-targeting agents in AML: progress and current therapeutic capacity
Ravindra Majeti, MD, PhD, Stanford University, Stanford, CA, discusses leukemia stem cell (LSC)-targeting therapies for the treatment of acute myeloid leukemia (AML). Although the specific targeting of LSCs holds promise for improving clinical outcomes, there is limited therapeutic application at this stage, and further investigation is required in order for any clinical benefits to be realized. Immunological approaches and targeting of molecular pathogenesis pathways are currently being explored. This interview took place at the American Association for Cancer Research (AACR) Annual Meeting 2024 in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
